Drug Approval | August 20, 2022
DCGI approves AstraZeneca 's Olaparib film-coated tablets
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
Subscribe To Our Newsletter & Stay Updated
